Synuxol-Nita

Synuxol-Nita has a broad-spectrum bactericidal activity against most Gram-positive and Gram-negative microorganisms, including strains producing β-lactamase:

Synuxol-Nita is used to treat infectious diseases of bacterial etiology in cats and dogs, including:

• skin diseases (including deep and superficial pyoderma)
• urinary tract infections
• respiratory infections of bacterial etiology (when both the upper and lower respiratory tracts are involved in the infectious process)
• enteritis of bacterial etiology, as well as infections of bacterial etiology which pathogens are sensitive to amoxicillin

Synuxol-Nita is used in cats and dogs perorally individually or with feed. Feed intake does not affect the bioavailability of the active substances of the drug. Synuxol-Nita is prescribed at a single dose of 12.5 mg (according to the sum of active substances) per 1 kg of animal body weight 2 times a day.

DOSAGES OF SYNUXOL-NITA ACCORDING TO ANIMAL BODY WEIGHT

Number of tablets per 1 animal per administration, pcs

In cases of hard-to-treat diseases (especially respiratory infections), a single dose of Synuxol-Nita should be increased to 25 mg (according to the sum of active substances) per 1 kg of animal body weight and administered twice a day. Treatment period is 5-7 days. In cases of chronic or hard-to-treat diseases (especially with deep pyoderma in dogs), the treatment period may last for 10-28 days.  

Contraindications and special instructions:
Simultaneous use of the veterinary drug with macrolides, tetracyclines, chloramphenicol and sulfonamides is not recommended due to a possible decrease in the effectiveness of amoxicillin.
It should not be used simultaneously with thiamphenicol, chloramphenicol, penicillin group antibiotics, cephalosporins and fluoroquinolones, as well as mixed in one syringe with other drugs.
In females during pregnancy and feeding of offspring, the veterinary drug is used, when necessary, under the supervision of a veterinarian based on an assessment of the ratio of the expected benefit to the possible risk of its use.